Infant Diet Recommendations Reduce IgE-Mediated Egg, Peanut, and Cow’s Milk Allergies

Background: Meta-analyses of randomized controlled trials have found that introducing eggs and peanuts earlier during infancy reduced egg and peanut allergy risk. Hence, infant feeding advice has dramatically changed from previous recommendations of avoidance to current recommendations of inclusion of common food allergens in infant diets. Objective: To compare the prevalence of IgE-mediated food allergies […]

Infant diet recommendations reduce IgE-mediated egg, peanut and cow’s milk allergies

Background: Meta-analyses of randomized controlled trials have found that introducing eggs and peanuts earlier during infancy reduced egg and peanut allergy risk. Hence, infant feeding advice has dramatically changed from previous recommendations of avoidance to current recommendations of inclusion of common food allergens in infant diets. Objective: To compare the prevalence of IgE-mediated food allergies […]

Walnut threshold dose distribution and safe dose in allergic patients (Nut CRACKER Study)

Background: Walnut is a significant global food allergen, but data relating to population reaction thresholds are limited. This hampers the ability of industry and regulators to undertake allergen risk assessment, increases use of allergen labeling, and impairs patient quality of life. Objective: To describe reaction eliciting doses in a large walnut-allergic population METHODS: Retrospective cohort […]

Open access online calculator predicts peanut allergic reactions with high accuracy

Background: The Peanut Allergy Prediction Web Tool is a newly developed online aid, which calculates the probability of an individual’s allergic reaction based on their SPT, Ara h 2-specific IgE (Ara h 2-sIgE) and/or basophil activation test (BAT) results. Objective: To validate the diagnostic performance of the online tool and assess its ability to discriminate […]

Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPE

Background: The pivotal phase 3 EPITOPE trial, a 12-month, double-blind, placebo-controlled study of epicutaneous immunotherapy with the VIASKIN® patch containing 250 μg peanut protein (VP250) previously reported significant treatment response vs placebo in peanut-allergic toddlers aged 1-through-3 years. Objective: To assess interim efficacy and safety of VP250 from the first year of the EPITOPE open-label […]

Successful introduction of peanut in sensitized infants with reported reactions at home

Background and objective: Previous studies have shown efficacy of early introduction of peanut to prevent peanut allergy. It is currently unknown which diagnostic pathway is optimal after parental-reported reactions to peanut at home after early introduction. Methods: The PeanutNL cohort study included high-risk infants that were referred for early introduction of peanut. A subgroup of […]

Trends of peanut-induced anaphylaxis rates before and after the 2017 early peanut introduction guidelines in Montreal, Canada

Background: Food allergies, particularly peanut, represent the predominant cause of anaphylaxis. While early allergen introduction has emerged as a potential preventive strategy, the precise impact of recent guidelines on peanut-induced anaphylaxis rates in Canada remains unclear. Objective: To assess the impact of the 2017 Addendum Guidelines for the Prevention of Peanut Allergy on peanut-induced anaphylaxis […]